World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Immunology

D-Index
144
Citations
89249
World Ranking
143
National Ranking
95

Medicine

D-Index
144
Citations
89367
World Ranking
1431
National Ranking
834

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2008 - Member of the National Academy of Sciences

Overview

Ronald Levy is affiliated with Stanford University in the United States, with a research focus spanning multiple fields and topics within medicine and biology. Their work primarily concentrates on oncology, immunology, and molecular biology, contributing extensively to the understanding and treatment of cancer and immune-related diseases.

The scientist's main fields of study include Medicine (103 publications), Immunology and Microbiology (38 publications), and Biochemistry, Genetics and Molecular Biology (37 publications). Their subfields of study highlight a strong focus on oncology (41 publications), immunology (35 publications), molecular biology (27 publications), pathology and forensic medicine (14 publications), and infectious diseases (13 publications).

Key research topics covered by Ronald Levy include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • RNA Interference and Gene Delivery
  • Cancer Immunotherapy and Biomarkers
  • SARS-CoV-2 and COVID-19 Research

Frequent co-authors in their publications are:

  • Debra K. Czerwinski (34 coauthored works)
  • Tanaya Shree (22 coauthored works)
  • Sarah Haebe (18 coauthored works)
  • Brock A. Martin (15 coauthored works)
  • Anuja Sathe (14 coauthored works)

Ronald Levy has published extensively in several notable scientific venues including:

  • Blood (13 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (5 publications)
  • Proceedings of the National Academy of Sciences (4 publications)
  • Clinical Cancer Research (3 publications)
  • Regular and Young Investigator Award Abstracts (3 publications)

Among recent papers representative of their research contributions are:

  • Intratumoral Immunotherapy for Early-stage Solid Tumors, 2020, Clinical Cancer Research
  • Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program, 2023, Journal of Clinical Oncology
  • Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma, 2020, American Journal of Hematology
  • Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma, 2021, Blood
  • Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?, 2020, European Journal of Cancer

Ronald Levy was awarded membership in the National Academy of Sciences in 2008, reflecting recognition by the scientific community.

Best Publications

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    P McLaughlin;A J Grillo-López;B K Link;R Levy

  • Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

    Frank J. Hsu;Claudia Benike;Francesco Fagnoni;Tina Marie Liles

  • IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

    David G. Maloney;Antonio J. Grillo-López;Christine A. White;David Bodkin

  • Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

    Wen-Kai Weng;Ronald Levy

  • Two populations of Ia-like molecules on a human B cell line.

    L A Lampson;R Levy

  • Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

    Richard A. Miller;David G. Maloney;Roger Warnke;Ronald Levy

  • Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

    DG Maloney;TM Liles;DK Czerwinski;C Waldichuk

  • Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

    Mark P. Chao;Ash A. Alizadeh;Chad Tang;June Helen Myklebust;June Helen Myklebust

  • IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

    Unknown

  • Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

    Izidore S. Lossos;Debra K. Czerwinski;Ash A. Alizadeh;Mark A. Wechser

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin

  • IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

    D G Maloney;A J Grillo-López;D J Bodkin;C A White

  • 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns

    Trevor Hastie;Robert Tibshirani;Michael B Eisen;Ash Alizadeh

  • Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

    John M. Timmerman;Debra K. Czerwinski;Thomas A. Davis;Frank J. Hsu

  • Dendritic Cell Vaccines for Cancer Immunotherapy

    John M. Timmerman;Ronald Levy

  • Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors

    Larry W. Kwak;Michael J. Campbell;Debra K. Czerwinski;Sarah Hart

  • Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

    J Yates;O Glidewell;P Wiernik;Cooper

  • A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients

    Andrew J. Gentles;Ash A. Alizadeh;Su In Lee;June Helen Myklebust

  • Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

    Thomas A. Davis;Christine A. White;Peter McLaughlin;Myron S. Czuczman

Frequent Co-Authors

Ash A. Alizadeh
Ash A. Alizadeh Stanford University
Shoshana Levy
Shoshana Levy Stanford University
Roger A. Warnke
Roger A. Warnke Stanford University
Ranjana H. Advani
Ranjana H. Advani Stanford University
Yasodha Natkunam
Yasodha Natkunam Stanford University
Robert Tibshirani
Robert Tibshirani Stanford University
David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
Chih Long Liu
Chih Long Liu Stanford University
Aurélien Marabelle
Aurélien Marabelle Institut Gustave Roussy
Maximilian Diehn
Maximilian Diehn Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Many students transition into nursing and advanced practice roles to complement their knowledge of the immune system. For example, 12-month accelerated nursing programs online for non nurses offer a fast track into nursing for individuals without a nursing background, making it easier to enter the field quickly.

Additionally, students seeking less competitive entry options might consider programs highlighted in easiest accelerated nursing programs or easy admission lpn programs. These pathways provide accessible routes to becoming a Licensed Practical Nurse or registered nurse, roles that often work closely with immunologists and researchers.

For advanced clinical roles, exploring the easiest fnp program can be beneficial. Family Nurse Practitioner programs blend patient care with specialized knowledge, allowing professionals to apply immunological principles in healthcare settings.

Best Scientists Citing Ronald Levy

Trending Scientists

Recently Published Articles